PROTAC BRD4 Degrader-43
PROTAC BRD4 Degrader-43 is a BRD4 PROTAC degrader. PROTAC BRD4 Degrader-43 recruits the DCAF1-DDB1-Cul4A E3 ligase complex via a Vpr-derived peptide moiety to induce BRD4 ubiquitination and degradation through the ubiquitin-proteasome system. PROTAC BRD4 Degrader-43 exhibits potent HIV latency-reversing activity. PROTAC BRD4 Degrader-43 can be used for the research of HIV-1 latent infection. (Pink: BRD4 ligand (HY-13030); Blue: Cul4A-DDB1-DCAF1 ligand (HY-P11640); Black: conjugate of PEG linker + cell-penetrating peptide (HY-P2483))
For research use only. We do not sell to patients.
- Formula: C151H251ClN60O41S2
- Molecular Weight:3662.57
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
All PROTACs Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
BRD4 |
In Vitro
PROTAC BRD4 Degrader-43 (Compound 11) (1-30 μM) degrades BRD4 in MCF-7 cells[1].
PROTAC BRD4 Degrader-43 has low cytotoxicity in MCF-7, J-Lat 10.6, and THP-1 NLuc#225 cells, with CC50 values ≥45 μM[1].
PROTAC BRD4 Degrader-43 (20-50 μM) exhibits potent HIV latency-reversing activity in J-Lat 10.6 and THP-1 NLuc#225 cells, with stronger activity in THP-1 NLuc#225 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
Molecular Weight 3662.57
-
Formula C151H251ClN60O41S2
-
SMILES
O=C([C@@H](NC(COCCOCCN[C@@H](CCCCNC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](N)CCCNC(N)=N)=O)CCCNC(N)=N)=O)CCCNC(N)=N)=O)CCCNC(N)=N)=O)CCCNC(N)=N)=O)CCCNC(N)=N)=O)CCCNC(N)=N)=O)CCCNC(N)=N)=O)C(COCCOCCOCCNC(C[C@H]1C2=NN=C(N2C3=C(C(C4=CC=C(C=C4)Cl)=N1)C(C)=C(S3)C)C)=O)=O)=O)CCSC)N[C@H](C(N[C@H](C(N[C@H](C(N5[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N6[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N7[C@H](C(N)=O)CCC7)=O)CCC(O)=O)=O)CCCNC(N)=N)=O)CCC(N)=O)=O)CCC6)=O)=O)CCC(N)=O)=O)CC(O)=O)=O)CCC(O)=O)=O)CCC5)=O)C)=O)CCC(N)=O)=O)CCC(O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
PROTAC BRD4 Degrader-43 Related Classifications
HY-181164 Related Classifications
Powered by Bioz